Bortezomib: a review of its use in patients with multiple myeloma.
about
Chemotherapy-induced peripheral neuropathy: an update on the current understandingRecent advancements of bortezomib in acute lymphocytic leukemia treatmentBortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouseThe ubiquitin proteasome system plays a role in venezuelan equine encephalitis virus infectionProteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectorsAuthorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFκB.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors.Deubiquitinating enzymes as promising drug targets for infectious diseases.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Novel systemic therapy against malignant pleural mesothelioma.The risk factors for herpes zoster in bortezomib treatment in patients with multiple myelomaInhibition of NF-κB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice.RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.Spondylocheirodysplastic Ehlers-Danlos syndrome (SCD-EDS) and the mutant zinc transporter ZIP13.A novel ER-microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression.Advances in diagnosing and managing antibody-mediated rejection.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Emerging drugs for the treatment of transplant rejection.Subcutaneous bortezomib: in multiple myeloma.Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Pomalidomide: first global approval.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.Protease-activated pore-forming peptides for the treatment and imaging of prostate cancerNrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic interventionCancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cellsA Mechanistic Understanding of Axon Degeneration in Chemotherapy-Induced Peripheral Neuropathy.Recruitment of APPL1 to ubiquitin-rich aggresomes in response to proteasomal impairment.
P2860
Q26740689-E10CAA52-D46A-4DEF-8A67-78386062ACE6Q26829613-3E7449F3-78F8-442A-BD2E-4D4EEC9CADDBQ28533426-2398113E-90C4-42A4-BA4A-21EF746E1802Q28546865-EF8B7BD6-40FD-47F4-AD40-9B167F44B805Q28730577-6875CEDB-B194-46A2-B965-FC59AFED7EEFQ33411100-2186D4A6-1391-41C9-8C3E-426336924B8AQ33678251-3B93F8BE-C6C2-4CF8-9FF5-9F4185C9B19BQ33692555-7DA5DA18-0B38-4BC5-9514-EDDB35AC501FQ33696772-8F7FC846-E58A-48D5-AA89-08386500C096Q33836097-418D0C49-A610-482A-ABE0-BB8EA6D8A40BQ33882390-4742EB97-44F7-4116-AC51-EFBF6662B746Q33890499-4036B6AB-689A-4AEB-803E-91C2367B37E3Q34316960-D623B0F9-C1B1-4D4F-9C87-A449E6A07185Q34768640-4316F139-3DF6-42CD-9F26-115FB96DCD25Q34870566-183B9BA5-CB86-44FC-86A9-FB253692B703Q35482141-58A28774-B1AF-4AAD-94A3-1F5F5859705EQ35528750-76E10607-0A67-463D-A886-960232B31D52Q35836872-C9C78574-B4D5-46DC-89B1-8B90CECE5E72Q35836881-2AE01B46-6C43-48D7-BF97-6ECD75A75E4BQ36084704-CD0CC3BE-4175-4D00-BE72-D91F193AB0A5Q36234799-1369A25C-2EAE-45D9-B986-9BAFA9F1E872Q36584633-61EEEA86-561B-42FE-8ADA-02CAAFFB46F9Q36882828-9D041591-514B-4B6A-A4FF-C4CFDFF42767Q37676032-C84CB5B0-9216-4EF6-A604-0406380C25F3Q37851944-CF826E6D-C023-4410-8E14-857535AA3729Q37960177-4A643AAB-02B1-4C4F-B1FA-039D76947F99Q38075800-BF2261F2-001B-4EB4-80A5-575C6047B043Q38086014-234F2609-2F40-4992-9C3A-D6E0FA257D77Q38097747-1BAA14F4-C7D9-4254-AC8C-EDB3959510E0Q38538693-AF59F2BC-5959-450A-BDEC-D7C85F3468B5Q38840423-25F388F0-2CDD-4119-A8B9-35B8E1AE5D43Q38911003-1D9E2530-0441-4161-9B11-BF1D69C303C2Q38925667-D4F9D726-2A12-4200-8480-16FC8DB3A24CQ38977283-1B73E929-8B0F-471D-8ED9-F5C67FC27E74Q39117277-CD5CC2DB-931B-4A16-9FD3-A5F7B40C6BB4Q39548450-11B6C9E8-7208-40F2-B1CC-55CD653FB701Q39748970-F80FE1B6-5479-4DE0-99C8-57373DC1951FQ41026661-B8AC02B2-047D-4278-A74D-42AB474F9D0DQ41606031-69FDC6E3-0B42-4D09-A456-C24AD8878D6CQ41853365-86CCD333-C1F8-4117-8BC8-F32EB6DED844
P2860
Bortezomib: a review of its use in patients with multiple myeloma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bortezomib: a review of its use in patients with multiple myeloma.
@ast
Bortezomib: a review of its use in patients with multiple myeloma.
@en
Bortezomib: a review of its use in patients with multiple myeloma.
@nl
type
label
Bortezomib: a review of its use in patients with multiple myeloma.
@ast
Bortezomib: a review of its use in patients with multiple myeloma.
@en
Bortezomib: a review of its use in patients with multiple myeloma.
@nl
prefLabel
Bortezomib: a review of its use in patients with multiple myeloma.
@ast
Bortezomib: a review of its use in patients with multiple myeloma.
@en
Bortezomib: a review of its use in patients with multiple myeloma.
@nl
P1433
P1476
Bortezomib: a review of its use in patients with multiple myeloma.
@en
P2093
Kate McKeage
Monique P Curran
P2860
P304
P356
10.2165/00003495-200969070-00006
P577
2009-01-01T00:00:00Z
P6179
1025828980